IP Library Granted Patent US 10,472,610
Granted Patent B2
US 10,472,610 · App. 15/311,759 · Granted Nov 12, 2019

Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells

Inventors: Kenji Osafune (Kyoto, JP); Taro Toyoda (Kyoto, JP)
Assignee: KYOTO UNIVERSITY
C12N5/0676A61K35/39C12N2501/11C12N2501/117C12N2501/155C12N2501/16C12N2501/41C12N2501/727C12N2501/999C12N2506/02Y02A20/402
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,472,610
App. No.
15/311,759
Granted
Nov 12, 2019
Kind
B2
Abstract

Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1 + /NKX6.1 − cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscle myosin II inhibitor.

Claims (17)

1. A method for generating pancreatic bud cells from pluripotent stem cells, comprising the following steps:

(1) culturing the pluripotent stem cells in a medium containing an activin;

(2) culturing the cells obtained in step (1) in a medium containing KGF;

(3) culturing the cells obtained in step (2) in a medium containing KGF, a BMP inhibitor, a retinoic acid derivative and a hedgehog pathway inhibitor, wherein the steps (1)-(3) are under an adherent culture condition; and

(4) dissociating the cells obtained in step (3) into single cells and culturing the dissociated cells under a suspension culture condition in a medium containing KGF, EGF and a BMP inhibitor.

2. The method according to claim 1 , wherein the medium containing an activin in step (1) further contains a GSK3 inhibitor.

3. The method according to claim 2 , wherein the GSK3 inhibitor is CHIR99021.

4. The method according to claim 1 , wherein the BMP inhibitor used in step (3) is Noggin.

5. The method according to claim 1 , wherein the retinoic acid derivative is TTNPB.

6. The method according to claim 1 , wherein the hedgehog pathway inhibitor is KAAD-cyclopamine.

7. The method according to claim 1 , wherein the medium in step (4) further contains a ROCK inhibitor or a nonmuscle myosin II inhibitor.

8. The method according to claim 7 , wherein the ROCK inhibitor selected from the group consisting of Y-27632, Fasudil, SR3677, GSK269962, and H-1152; or the nonmuscle myosin II inhibitor is blebbistatin.

9. The method according to claim 8 , wherein the ROCK inhibitor is Y-27632 and the concentration of Y-27632 in the medium is 20-100 μM.

10. The method according to claim 1 , wherein the medium in step (4) further comprises a TGFβ inhibitor.

11. The method according to claim 1 , wherein the TGFβ inhibitor is ALK5 inhibitor II.

12. The method according to claim 1 , wherein the pancreatic bud cells are PDX1+and NKX6.1+.

13. The method according to claim 1 , wherein the pluripotent stem cells are human cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: OSAFUNE, KENJI; TOYODA, TARO
To: KYOTO UNIVERSITY
Reel/Frame 040361/0893 →
Priority Claims (1)
JP 2014-105049 · May 21, 2014 · national
Continuity (1)
Related Publication 20170175082A1 · Jun 22, 2017